ReviewPreprint
This review paper examines the pharmacological mechanisms, safety profiles, and regulatory status of both approved and unapproved peptide therapies relevant to sports medicine, musculoskeletal injury recovery, and athletic performance enhancement. The compounds reviewed span a wide spectrum — from FDA-approved agents such as tesamorelin and sermorelin, to gray-market compounds including BPC-157, TB-500, CJC-1295, Ipamorelin, AOD-9604, FS-344, GHK-Cu, MOTS-C, and SS-31. The authors note that while many unapproved peptides show promising results in preclinical and animal models — including favorable tissue repair and metabolic effects — rigorous human safety and efficacy data remain scarce. The review highlights a growing direct-to-consumer gray market operating outside regulatory oversight and discusses how social media may amplify perceived benefits through placebo-related mechanisms. The paper also offers a clinical framework to guide patient conversations and support evidence-based decision-making. Key limitations include the inherent constraints of a narrative review design, reliance on heterogeneous preclinical data for unapproved compounds, and the absence of controlled human trials for most of the highlighted peptides.
Unknown journal · Dec 2025DOI ↗ In vitroPreprint
This paper proposes a molecular mechanism for BPC-157, a synthetic 15-amino-acid peptide previously studied in preclinical models for regenerative and cytoprotective effects. The authors hypothesize — based on computational structural modeling and in silico docking — that BPC-157 adopts a polyproline II (PPII) helix conformation and engages the SH3 domains of Src family kinases (c-Src, Yes, Fyn). The proposed interaction is suggested to relieve autoinhibition of these kinases, potentially activating downstream FAK-ERK and PI3K-Akt signaling pathways. To build a tool for future experimental testing, the authors engineered an mCherry-BPC157₂ fusion protein, encoded it in a baculovirus vector, and expressed it in insect (Sf9) cells. Expression was confirmed by fluorescence imaging and western blot at the expected ~31 kDa size. Importantly, this study does not include human subjects, animal experiments, or in vitro binding assays — the core mechanistic claims rest entirely on computational modeling. The fusion protein work is a proof-of-concept for a future experimental reagent. Findings should be interpreted as hypothesis-generating only.
Unknown journal · Dec 2025DOI ↗ ▶ Video
In this educational video, Canadian physicians Dr. Brad and Dr. Paul from the "Talking With Docs" YouTube channel offer their opinion on the peptide BPC-157 (Body Protective Compound-157), a 15-amino-acid fragment naturally found in the stomach. They explain that while BPC-157 has gained significant popularity through social media and biohacking communities, it is not FDA or Health Canada approved for human use, and is banned by WADA. The doctors acknowledge that in vitro and animal studies suggest potential benefits such as tissue repair, angiogenesis, and reduced inflammation, but emphasize there are no well-conducted human clinical trials demonstrating efficacy. The only human data includes a small Phase 1 safety trial and a limited 12-person knee injection study with weak methodology. The doctors raise concerns about unregulated sourcing, potential contamination, sterility risks from self-injection, and a theoretical link between the compound's tissue-growth properties and carcinogenesis. They advise against using BPC-157 and suggest proven alternatives for injury recovery. This video represents the hosts' informed opinions and is not a peer-reviewed study.
YouTube · Dec 2025Watch ↗ Animal only
This paper introduces a novel conceptual framework called the "triad" — linking corneal ulcer healing, corneal neovascularization, and intraocular pressure — and extends it to avascular tissue healing, using tendon as a parallel model. The authors propose cytoprotection as a unifying therapeutic principle and use the stable gastric pentadecapeptide BPC 157 as a primary illustrative agent. Drawing on preclinical studies, the paper describes findings in which BPC 157 reportedly normalized elevated intraocular pressure in glaucomatous rats, preserved retinal integrity, restored pupil function, maintained corneal transparency during ulcer or abrasion healing, and counteracted corneal neovascularization and dry eye. The paper also systematically maps a broad range of existing standard therapeutic agents — including ascorbate, fibronectin, EGF, anti-VEGF agents, corticosteroids, prostaglandin analogs, and Rho-kinase inhibitors — onto this triad to highlight shared pathways and inconsistencies across drug classes. The work is framed as a theoretical and narrative synthesis of preclinical data rather than a new clinical trial, and the authors explicitly call for further translational research before clinical application. Key limitations include the absence of human trial data and reliance on animal models.
Pharmaceuticals (Basel, Switzerland) · Nov 2025DOI ↗ In vitroPreprint
This paper proposes a molecular mechanism for BPC-157, a synthetic pentadecapeptide previously studied in preclinical settings for regenerative and cytoprotective properties. The authors use structural modeling and in silico docking to hypothesize that BPC-157 adopts a polyproline II (PPII) helix conformation that enables it to bind the SH3 domains of Src family kinases (SFKs), including c-Src, Yes, and Fyn. According to this model, such binding would relieve SH3-mediated autoinhibition of these kinases, triggering downstream FAK-ERK and PI3K-Akt signaling cascades associated with cell survival and repair. To build a tool for future experimental validation, the researchers engineered an mCherry-BPC157₂ fluorescent fusion protein, encoded it in a baculovirus vector, and expressed it in Sf9 insect cells. Expression was confirmed by fluorescent imaging and western blot at the predicted ~31 kDa molecular weight. Notably, no binding interaction or functional activity in mammalian systems was experimentally demonstrated; the SH3 engagement hypothesis remains computational. Limitations include the absence of human or animal data, reliance on in silico docking, and use of an insect cell expression system solely for protein production validation.
Unknown journal · Nov 2025DOI ↗ Animal only
This paper is a commentary responding to a previously published literature and patent review by Józwiak et al. (Pharmaceuticals 2025) that raised concerns about BPC 157, a stable synthetic gastric pentadecapeptide. The authors defend BPC 157's therapeutic profile, arguing that the reviewed concerns — specifically that it promotes pathological angiogenesis, elevates nitric oxide (NO) and eNOS toward damaging free radical formation, and may contribute to tumorigenesis or neurodegenerative diseases — are speculative and contradicted by existing preclinical evidence. The authors frame BPC 157 as a cytoprotective agent rooted in Robert's and Szabo's cytoprotection concept, emphasizing its alleged pleiotropic effects across organ systems. They argue that BPC 157 modulates rather than indiscriminately amplifies angiogenesis and the NO system, citing animal model studies on wound healing, corneal transparency, anti-tumor effects (per Folkman's concept), and counteraction of Parkinson's- and Alzheimer's-like disturbances in mice and rats. The paper reports a high safety profile (LD50 not achieved in animal studies). Key limitations include that this is a narrative commentary relying heavily on preclinical data, with no new human clinical trial data presented and no controlled experimental methodology introduced.
Pharmaceuticals (Basel, Switzerland) · Sep 2025DOI ↗ Insufficient
This paper is a published correspondence ("Reply") in the journal Pharmaceuticals, in which the original authors of a literature and patent review on the BPC 157 peptide respond to a commentary submitted by Sikiric et al. The reply addresses points raised in the comment regarding BPC 157's proposed mechanisms of action, specifically its purported roles in modulating angiogenesis and nitric oxide (NO) pathways. The responders engage with the argument that BPC 157 may selectively target the cytotoxic and damaging aspects of NO signaling while preserving or restoring its essential protective physiological functions. As a correspondence piece reacting to a comment on a review article, this paper does not present new experimental data, clinical trials, or original preclinical findings. Its contribution is interpretive and editorial in nature, clarifying the scope and conclusions of the original review in light of the mechanistic claims put forth by the commentators. Limitations include the absence of any new empirical evidence; all mechanistic claims discussed are derived from previously published literature cited by both parties.
Pharmaceuticals (Basel, Switzerland) · Sep 2025DOI ↗ Limited · human
This IRB-approved pilot study investigated the safety of intravenous (IV) administration of BPC-157 (Body Protection Compound 157) in humans. Two participants — a 58-year-old Asian male and a 68-year-old Caucasian female, both with prior IV BPC-157 exposure — received escalating doses over two consecutive days at a private clinic in Florida. Baseline and follow-up fasting blood work and vital signs were collected across three days. The researchers measured biomarkers related to heart, liver, kidney, and thyroid function, as well as blood glucose. Both participants reportedly tolerated the infusions without any adverse side effects, and no clinically meaningful changes in the monitored biomarkers were observed. The authors conclude that IV BPC-157 appeared safe and well-tolerated in these two individuals and call for larger studies to confirm these findings. Key limitations are substantial: the study included only two participants with prior BPC-157 exposure, lacked a control group, had no blinding, involved a very short observation window (three days), and was conducted at a single private clinic. These factors severely restrict the generalizability of the findings and preclude any broad conclusions about safety or efficacy.
Alternative therapies in health and medicine · Sep 2025Source ↗ Limited · human
This systematic review examined the existing literature on BPC-157 (Body Protection Compound-157), a naturally occurring gastric pentadecapeptide, specifically through the lens of orthopedic sports medicine. Researchers searched PubMed, Cochrane, and Embase for English-language studies published from database inception through June 2024. Of 544 identified articles, 36 met inclusion criteria — 35 preclinical studies and only 1 clinical study. Preclinical findings suggested BPC-157 may enhance growth hormone receptor expression, promote angiogenesis, stimulate cell growth pathways, and reduce inflammatory cytokines, with improved functional, structural, and biomechanical outcomes reported across muscle, tendon, ligament, and bone injury models. The sole clinical study was a retrospective case series in which 7 of 12 patients reported musculoskeletal pain relief lasting more than 6 months following intraarticular injection for chronic knee pain. The compound was found to be hepatically metabolized with a half-life under 30 minutes and renally cleared. Preclinical safety data showed no adverse effects across multiple organ systems; no clinical safety data were identified. The authors note that BPC-157 lacks FDA approval and is banned in professional sports, and caution about risks from unregulated manufacturing. The review is limited almost entirely to preclinical evidence, leaving significant gaps in human safety and efficacy data.
HSS journal : the musculoskeletal journal of Hospital for Special Surgery · Jul 2025DOI ↗ Animal only
This review paper examines the proposed therapeutic mechanisms and safety profile of BPC 157, a synthetic 15-amino-acid peptide derived from a gastric protein. The authors argue, drawing on Robert and Szabo's cytoprotection concept, that BPC 157's protective effects on gastric epithelial and endothelial cells extend to other organ systems (cytoprotection → organoprotection). The paper addresses and disputes concerns that BPC 157 might promote tumorigenesis through angiogenesis, generate harmful free radicals via increased nitric oxide (NO) and eNOS activity, or contribute to neurodegenerative diseases such as Parkinson's and Alzheimer's. Instead, the authors contend that, based on reviewed animal and in vitro studies, BPC 157 modulates angiogenesis in a context-dependent manner—maintaining corneal transparency and opposing pathological neovascularization—while demonstrating anti-tumor effects both in vivo and in vitro per Folkman's framework. The paper also reports that BPC 157 counteracts Parkinson's- and Alzheimer's-like disturbances in rodent models and modulates NO levels without promoting damaging free radical formation. Key limitations include the heavy reliance on animal and in vitro data, the absence of human clinical trial data, and the authors' advocacy framing.
Pharmaceuticals (Basel, Switzerland) · Jun 2025DOI ↗ Animal only
This review paper examines pharmacotherapies for abdominal compartment syndrome (ACS) and intra-abdominal hypertension (IAH) through the lens of cytoprotection theory, framing these conditions as failures of cytoprotective mechanisms. The authors survey existing pharmacological agents used in ACS/IAH management, noting that most currently reported treatments are limited in scope—typically effective in only one organ, tested only in mild-to-moderate IAH, applied prophylactically rather than therapeutically, and lacking confirmed broad effectiveness. The review then focuses on stable gastric pentadecapeptide BPC 157 as a proposed cytoprotective agent with claimed pleiotropic effects. The authors argue that BPC 157 may address multiple simultaneous targets in ACS/IAH, including compression/ischemia and decompression/reperfusion injury across several organs (brain, heart, lung, liver, kidney, gastrointestinal tract). A proposed mechanism involving activation of collateral "bypassing" vascular pathways—particularly azygos vein blood flow—is described as a potential key to counteracting multiorgan failure, vascular dysfunction, thrombosis, and free radical damage. The paper is a narrative review drawing primarily on animal study data; it does not present original clinical trial data or human evidence. Conclusions about BPC 157 efficacy are therefore speculative in a human clinical context.
Pharmaceuticals (Basel, Switzerland) · Jun 2025DOI ↗ Review
This literature and patent review examines BPC 157 (Body Protection Compound 157), a synthetic pentadecapeptide derived from human gastric juice. The authors surveyed preclinical evidence across multiple disease models, including tissue injury, inflammatory bowel disease, and central nervous system disorders, cataloguing the compound's reported pleiotropic (wide-ranging) biological activities and proposed mechanisms of action. The review also assesses available toxicity and safety data, noting that relatively few side effects have been reported in preclinical settings. Regulatory context is highlighted: BPC 157 has not been approved by the FDA or equivalent global authorities, as no sufficient clinical trials in humans have been completed. The compound was temporarily listed by the World Anti-Doping Agency (WADA) in 2022 but is no longer on the banned list. The authors additionally map recent patent applications and granted patents to reflect growing commercial and research interest. A key limitation acknowledged throughout is that virtually all supporting evidence comes from animal and in vitro studies, meaning the translation of these findings to human health outcomes remains unestablished.
Pharmaceuticals (Basel, Switzerland) · Jan 2025DOI ↗ Insufficient
This entry corresponds to a withdrawn article originally submitted to the journal Current Neuropharmacology, investigating the use of the stable gastric pentadecapeptide BPC 157 as a potential therapy for severe electrolyte disturbances in rats. The article was retracted at the authors' own request, and the publisher (Bentham Science) provided no details regarding the specific findings, data, or conclusions of the original study. Because the full content of the paper is unavailable — replaced entirely by a withdrawal notice — no experimental methods, results, or conclusions can be evaluated or attributed to the study. The withdrawal notice also includes standard publisher boilerplate regarding submission conditions and plagiarism policy, but does not disclose the reason for withdrawal. As a result, this record cannot be used to draw any conclusions about BPC 157's effects on electrolyte disturbances. Researchers and educators should treat this citation as non-existent in the evidence base, as the underlying data and claims are no longer accessible or endorsed by the authors or publisher.
Current neuropharmacology · Jan 2025DOI ↗ Animal only
This rat study investigated whether the stable gastric pentadecapeptide BPC 157, administered orally, could promote reattachment of the quadriceps muscle to bone following surgical detachment in rats. The model involved both complete detachment of the rectus femoris muscle and partial detachment of the vastus muscles. Untreated control animals exhibited persistent healing failure, including impaired walking and permanent knee flexure across all observation time points (1 day through 90 days post-injury). In contrast, animals receiving oral BPC 157 (at two dose levels) showed consistent improvement across macro- and microscopic analysis, ultrasound, MRI, biomechanical testing, and functional walking assessments. The authors report that treated animals showed early muscle-to-bone approximation, elimination of leg contracture, and progressive tissue reorganization, including periosteal reactivation and mesenchymal cell proliferation by day 3, and well-organized cortical bone with mature, parallel-oriented muscle fibers by 3 months. Key limitations include exclusive use of an animal model with no human data, lack of blinding details, and relatively small group sizes typical of preclinical peptide research. The findings are attributed solely to the study authors and do not establish clinical efficacy or safety in humans.
Pharmaceutics · Jan 2025DOI ↗ Insufficient
This cross-sectional pilot study examined the direct-to-consumer market for compounded glucagon-like peptide-1 (GLP-1) receptor agonists in Colorado. Researchers conducted Google searches of business websites advertising compounded GLP-1 products for weight loss across census-defined statistical areas between March and April 2024. They identified 93 websites corresponding to 188 physical locations. Most businesses were categorized as medical/health spas or weight loss services. Semaglutide was the most commonly advertised product (92/93 sites), followed by tirzepatide (40/93). Some sites advertised combination formulations including B vitamins, BPC-157 (flagged by the FDA as unsafe for compounding), and other additives. Seven sites advertised oral formulations. Notably, 41 of 93 websites referenced FDA approval in their product descriptions—a potentially misleading claim, as compounded products are not FDA-approved—and 5 sites incorrectly referred to products as "generic." The study's limitations include its focus on a single state, reliance on publicly available website data, and its pilot/cross-sectional design, which limits generalizability. The authors conclude that regulatory action is needed to address misleading advertising and safety concerns in this market.
Journal of pharmaceutical policy and practice · Dec 2024DOI ↗ Animal only
This review paper examines the published preclinical evidence on stable gastric pentadecapeptide BPC 157 as a potential therapeutic agent for intestinal anastomoses and related gastrointestinal conditions in rat models. The authors summarize findings across a range of anastomosis types — including esophagogastric, colocolonic, jejunoileal, and ileoileal — and report that BPC 157 therapy was associated with improved healing outcomes in these animal studies. The review also covers concomitant gastrointestinal disturbances such as esophagitis, sphincter dysfunction, colitis, short bowel syndrome, and major vessel occlusion, as well as dysfunction of the nitric oxide and prostaglandin systems. Additionally, the authors discuss fistula healing (e.g., colocutaneous, gastrocutaneous, vesicovaginal, rectovaginal) as a related phenomenon, framing fistulas as abnormal anastomoses between tissues. The review concludes that both anastomoses and fistulas showed healing responses attributed to BPC 157 in rat models. Limitations include the exclusive reliance on animal data, absence of human clinical trials, and the inherent interpretive limitations of a narrative review format. No controlled human evidence is presented or discussed.
Pharmaceuticals (Basel, Switzerland) · Aug 2024DOI ↗ Animal only
This review paper examines the proposed mechanisms underlying the wide-ranging (pleiotropic) biological effects of BPC 157, a synthetic 15-amino-acid peptide described as stable in human gastric juice. The authors attempt to frame BPC 157's observed effects within classical neurotransmitter criteria — including production, release, receptor interaction, and clearance — while acknowledging that direct conclusive evidence meeting these criteria is lacking. Instead, the paper compiles a network of interconnected preclinical evidence suggesting that BPC 157 may counteract disturbances across multiple neurotransmitter systems, including dopamine, serotonin, glutamate, GABA, adrenaline/noradrenaline, acetylcholine, and the nitric oxide (NO) system. The paper also discusses potential receptor interactions (e.g., VEGF and growth hormone receptors) and observations related to nerve-muscle and nerve-nerve relationships in various experimental models. The authors draw parallels between BPC 157's activity and gasotransmitter behavior. A key limitation explicitly noted by the authors is the absence of direct human clinical trial data; the evidence base relies predominantly on animal and in vitro studies. This paper does not establish clinical efficacy or safety in humans.
Pharmaceuticals (Basel, Switzerland) · Apr 2024DOI ↗ In vitro
This study developed and validated a novel analytical strategy for characterizing how BPC-157 — a peptide classified as a doping agent — is metabolized in laboratory (in vitro) conditions. The researchers used stable isotope labeling (¹³C/¹⁵N-labeled BPC-157) combined with ultra-high-performance liquid chromatography–high-resolution mass spectrometry (UHPLC-HRMS) to systematically identify metabolites without needing prior knowledge of metabolic pathways. Using two in vitro incubation models, the study identified nine total metabolites: eight arising from conventional amide-bond cleavage and one from a previously unreported metabolic pathway. The team then developed and validated a detection method for BPC-157 and five key metabolites in human urine, achieving detection limits of 0.01–0.11 ng/mL and strong quantitative performance. Importantly, this was an entirely in vitro study; no human participants or animals were involved, meaning the metabolic profile observed may not fully reflect what occurs in the human body. The findings are primarily relevant to anti-doping laboratories seeking improved detection targets and analytical workflows, and do not speak to the biological effects or clinical utility of BPC-157.
Molecules (Basel, Switzerland) · Oct 2023DOI ↗ 🧪 TrialInsufficient
Registered Phase 1 interventional trial (unknown). Phase I clinical trial in healthy volunteers to study safety and pharmacokinetics of BPC-157, a pentadecapeptide from gastric source.
ClinicalTrials.gov · Dec 2015View trial ↗